th those who experience vascular occlusive events; 2) a prospective observation assessing the incidence of vascular occlusive events associated with Iclusig with or without anticoagulant or antiplatelet agents; 3) a follow-up of patients who were previously enrolled in the Phase I, I I, and III (EPIC) s

nd Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement with the FDA for immediate reauthorization of Iclusig marketing in the United States, with a narrower label and accompanying Risk Mitigation Strategy (REMS) and post- marketing requirements (PMRs). Aria

s - $13k per Euro 1mm. (indicative levels only, subject to market movement) ARIA - down 50% (-'$2.30 in pre) on reports that the co is discontinuing Iclusig marketing in the US FB - -$46.66 (down 4.5%) posted solid Q3 EPS of $0.25 vs. $0.19 cons. Stock was volatile in the aftermarket, dropping -15% afte

expected Yellen nOrnInation Ratiten &Wee :Tau EDI) • ARIAD Phatmaceulkals, Inc. Conlerence Cato Discuss Changes in Clinical Development Program of Iclusig scheduled for 8:33 am ET today cceN ;reed • EDT, httplrfl nance.yahoo.com/q?s-tARLASql • I meterite dolt I(7 SPEED2 CD Comparison [MY % Chg

our thoughts. ARIA = struggling to hold yesterday's 15% rally (—$4.11) after an FT article over the weekend cited an expected amended manuscript on Iclusig's Phase II PACE trial Expected in the 11/7 edition of the in the New England Journal of Medicine. Tazia Source: Bloomberg, 10/29/13 Tazia Smith D

s - $13k per Euro 1mm. (indicative levels only, subject to market movement) ARIA - down 50% (-'$2.30 in pre) on reports that the co is discontinuing Iclusig marketing in the US FB —$46.66 (down 4.5%) posted solid Q3 EPS of $0.25 vs. $0.19 cons. Stock was volatile in the aftermarket, dropping - 15% after

ts —$13k per Euro 1mm. (indicative levels only, subject to market movement) ARIA - down 50% (- $2.30 in pre) on reports that the co is discontinuing Iclusig marketing in the US FB - —$46.66 (down 4.5%) posted solid Q3 EPS of $0.25 vs. $0.19 cons. Stock was volatile in the aftermarket, dropping - 15% aft